Mizuho raised the firm’s price target on Hologic (HOLX) to $75 from $70 and keeps an Outperform rating on the shares post the earnings report. The firm says the company’s portfolio turnaround lagging into early next year are likely to keep the shares range bound .
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic’s Mixed Financial Outlook: Hold Rating Amid Growth Concerns and Margin Declines
- Hologic’s Growth Potential: Strong Q3 Results and Positive Outlook Justify Buy Rating
- Hologic Reports Strong Q3 2025 Earnings, Exceeds Guidance
- Hologic reports Q3 adjusted EPS $1.08, consensus $1.05
- Hologic sees Q4 adjusted EPS $1.09-$1.12, consensus $1.07